PIRLONG-PD Safety and Efficacy of Piribedil in Parkinson's Disease During Long Term Therapy
Status:
Completed
Trial end date:
2015-02-01
Target enrollment:
Participant gender:
Summary
Non-Ergot Dopamine agonists are meanwhile the drugs of first-choice in the treatment of
Parkinson's disease. The receptor profile of the non-ergot dopamine-agonist piribedil is
unique. In addition to agonistic effects on dopaminergic D2- and D3-receptors piribedil has
adrenergic alpha-2A- and alpha-2C-receptors antagonisic properties. There is evidence from
the literature that the antagonistic properties of piribedil are correlated with an
improvement of cognitive function and vigilance parameters in parkinson's disease. The aim of
the present non-interventional study is to investigate the safety and efficacy of piribedil
during long-term therapy of patients with M. Parkinson under consideration of cognitive
functions and quality of life.